United Therapeutics is a leader in PAH treatments, with Tyvaso being the primary revenue driver. Check out why I rate UTHR ...

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate ...

Completed pre-BLA meeting with FDA with full alignment on content of BLA, including CMC module, and path for fourth quarter 2024 rolling BLA submission for PRGN-2012† ...

Omega Therapeutics is halting work on its only clinical-stage candidate as part of a strategic refocus centered on three ...

I-Mab, a U.S.-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies ...

Should you forget Eli Lilly and buy this magnificent biotech instead? Let's find out.

An international, phase 3 clinical trial led by investigators at Mass General Brigham could improve the treatment of a rare disease that can cause debilitating symptoms.

Operator Good afternoon, ladies and gentlemen, and welcome to the Inovio third quarter 2024 financial results conference call ...

Most discontinued anti-tau antibodies (red) targeted tau’s N-terminus. Of the antibodies currently in trials (green), bepranemab and E2814 presented results at CTAD, while JJ-63733657/posdinemab and ...

Top-line data for its phase 2b trial studying GH001 is expected either in the fourth quarter of 2024 or the first quarter of ...

Clinical development and trial testing of vesleteplirsen (SRP-5051) for Duchenne muscular dystrophy (DMD) was stopped, with ...